Dynex Capital Inc (NYSE:DX) announced a monthly dividend on Monday, July 8th, Zacks reports. Investors of record on Monday, July 22nd will be given a dividend of 0.18 per share by the real estate investment trust on Thursday, August 1st. This represents a $2.16 annualized dividend and a yield of 12.48%. The ex-dividend date is Friday, July 19th.
Dynex Capital has decreased its dividend payment by an average of 9.5% per year over the last three years. Dynex Capital has a payout ratio of 304.2% meaning the company cannot currently cover its dividend with earnings alone and is relying on its balance sheet to cover its dividend payments. Analysts expect Dynex Capital to earn $2.04 per share next year, which means the company may not be able to cover its $2.16 annual dividend with an expected future payout ratio of 105.9%.
DX opened at $17.31 on Thursday. The stock has a market capitalization of $422.18 million, a P/E ratio of 7.33 and a beta of 0.62. Dynex Capital has a 52-week low of $16.23 and a 52-week high of $20.46. The firm’s fifty day moving average is $11.62.
Dynex Capital (NYSE:DX) last posted its quarterly earnings data on Wednesday, May 1st. The real estate investment trust reported $0.54 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.54. The business had revenue of $13.68 million for the quarter. Dynex Capital had a negative net margin of 71.70% and a positive return on equity of 13.53%. Analysts forecast that Dynex Capital will post 2.04 earnings per share for the current year.
Several research firms have issued reports on DX. Nomura decreased their price objective on shares of Carnival from $66.00 to $61.00 and set a “buy” rating on the stock in a report on Wednesday, March 27th. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. LADENBURG THALM/SH SH set a $220.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $20.12.
Dynex Capital Company Profile
Dynex Capital, Inc, a mortgage real estate investment trust, invests in mortgage-backed securities (MBS) on a leveraged basis in the United States. It invests in agency and non-agency MBS consisting of residential MBS, commercial MBS (CMBS), and CMBS interest-only securities. Agency MBS have a guaranty of principal payment by an agency of the U.S.
Featured Story: What is the Rule of 72?
Receive News & Ratings for Dynex Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynex Capital and related companies with MarketBeat.com's FREE daily email newsletter.